Abstract 6014
Background
The FGF signaling network plays a key role in tumorigenesis and is recognized as a potential therapeutic target. FGF23 is predominately expressed in bone osteocytes and can act as an autocrine, paracrine and/or endocrine growth factor in cancer. In this study, we aimed to assess the role of circulating FGF23 levels in the prognosis of cancer patients with bone metastases.
Methods
This study included a cohort of 112 patients with cancer (63% breast;16% prostate) and metastatic bone disease treated with bone targeting agents (BTA), in which serum baseline FGF23 was quantified by ELISA and further dichotomized in two groups (FGF23high and FGF23low). Cut-off was defined by mean + one standard deviation. The association of FGF23 with overall survival (OS) and with time to skeletal related events (TTSRE) was investigated. Time to event outcomes was calculated using the Kaplan-Meier method and tested using univariate/multivariate Cox regression models controlling for established prognostic factors across patients with solid tumors and bone metastases: extra-bone involvement, urinary N-terminal telopeptide (uNTX), presence of bone fractures, and calcemia.
Results
Mean FGF23 was 38.16 ± 26.15 pg/mL (interquartile range [IQR] 19.77-50.72). 16.8% of patients were classified as FGF23high (n = 19). Baseline characteristics were balanced between groups, except for the median uNTX level, which was higher in the FGF23high group (824.30 vs 118.02 nmol BCE/mmol creatinine, p = 0.040). Median time from beginning of BTA was similar between groups (1.28 vs 1.10 months, p = 0.161). After a median follow-up of 26.0 months (IQR 13.0-47.0), median OS was 34.4 months in the FGF23low group and 12.2 months in the FGF23high group (multivariate HR 0.18, 95% CI 0.07 – 0.44, p = 0.001; univariate p = 0.001). As a continuous variable, FGF23 at baseline kept its prognostic association (p = 0.001). Patients with FGF23low status at baseline had a longer TTSRE (13.0 vs 2.0 months, p = 0.04).
Conclusions
In this exploratory cohort, patients in the FGF23low group had a longer OS and TTSRE. Further studies are warranted to define its role as a prognostic biomarker and as a potential predictor of response to drugs targeting the FGF axis.
Clinical trial identification
Legal entity responsible for the study
Instituto de Medicina Molecular.
Funding
Has not received any funding.
Editorial Acknowledgement
Joana Cavaco Silva - Medical Writer (Medical Oncology Department - Hospital de Santa Maria - Centro Hospitalar Lisboa Norte).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract